# ExpressionEdits Partners with Boehringer to Enhance Gene Therapies with AI-Based Intron Design
## Key Points:
– U.K.-based ExpressionEdits has struck a deal with Boehringer Ingelheim.
– The partnership aims to leverage ExpressionEdits’ AI-based platform for designing introns.
– The introns are intended to enhance protein expression for new gene therapies.
– Boehringer Ingelheim is developing these gene therapies for undisclosed targets.
### Author’s Take:
The collaboration between ExpressionEdits and Boehringer Ingelheim marks a significant step in harnessing AI technology to optimize gene therapy development. By focusing on enhancing protein expression through intricately designed introns, this partnership sets the stage for potentially groundbreaking advancements in the field of genetic engineering.
Click here for the original article.